CD8A and type 1 diabetes mellitus: In contrast, identifying specific CD8+ T cells by scRNA-seq technology with TCR sequencing and modifying them by technologies such as CRISPR/Cas9, CAR-T, and TCR-T, making it possible to cure T1D by losing the ability to recognize β cells to β cell-specific stem-like CD8+ T cells and its differentiated progeny, is a potential pathway.